Game-Changing RSV Shot for Kids Nears Finish Line

The FDA on Monday announced the approval of the first injection designed to prevent RSV infections in healthy infants and toddlers. Beyfortus, developed by AstraZeneca and marketed by Sanofi, was cleared by the FDA for use in children up to the age of 24 months for preventing RSV infections. This is the first RSV drug for healthy children to be approved by regulators. Earlier this year, two RSV vaccines for seniors were approved by the FDA. The newly approved medication is a single-dose monoclonal antibody. It is not a vaccine but works in a similar way. The shot will likely provide comfort to many parents following last year’s surge, when small children unexposed to the virus were infected and hospitals scrambled to find room for all of them. Read more from The Hill here.